Resistin levels in perivascular adipose tissue and mid-term mortality in patients undergoing coronary artery bypass granting (original) (raw)
Related papers
Plasma levels of resistin predict cardiovascular events
Romanian Review of Laboratory Medicine, 2014
the incidence of the new ischemic cardiovascular events. Results: In patients with CAD, as compared with PAD, baseline plasma levels of leptin were significantly increased (2882.02 ± 368.57pg/ml vs 1025.56 ± 232.28 pg/ml; p<0.001), plasma levels of resistin were significantly decreased (13.15 ± 0.83ng/ml vs 17.76 ± 2.13 ng/ml; p = 0.02) and no differences in plasma levels of adiponectin and TNF-α were found. A significant correlation between BMI and plasma levels was found only for leptin, irrespective of group. 45 patients (49.5%) were re-hospitalized in a 2 years period of follow-up. In a backward stepwise multivariable Cox regression analysis only resistin ≥ 15 ng/ ml, HR =1.8829, 95% CI 1.0490-3.3797, p = 0.034 and diastolic blood pressure ≥ 85 mmHg, HR =2.0927, 95%CI 1.0782-4.0616, p=0.0299 were associated with new cardiovascular events. Conclussion: In patients with clinical atherosclerosis plasma levels of resistin predict new ischemc events. Rezumat Introducere: Un număr de citokine şi adipokine secretate de ţesutul adipos pot influenţa direct peretele vascular. Adiponectina exercită efecte anti-inflamatorii şi ateroprotective. Resistina este exprimată în cantităţi crescute în celulele inflamatorii. Resistina activează direct endoteliul prin suprareglarea moleculelor de adeziune, induce producţia de TNF-α în macrofage, efecte antagonizate de adiponectină. Leptina are multe efecte asupra celulelor din peretele arterial, unele similare cu efectele resistinei. Rolul prognostic al adipokinelor în ateroscleroză nu este bine precizat. Metode: Nivelele bazale ale adiponectinei, resistinei, leptinei şi TNF-α (ELISA) la pacienţi cu
Prognostic value of serum resistin levels in patients with acute myocardial infarction
Kardiologia Polska, 2014
Background: Resistin is a novel adipokine that is suggested to be involved in inflammatory conditions and atherosclerosis. Aim: To investigate the prognostic importance of resistin in acute myocardial infarction (AMI) patients. Methods: Resistin levels were measured in a population of 132 patients with AMI, of whom 72 (54%) had a diagnosis of ST elevation myocardial infarction (STEMI), and 60 (46%) had non-ST elevation myocardial infarction (NSTEMI). Thirty-three consecutive subjects who were referred to elective coronary angiography due to chest pain evaluation with normal coronary angiograms served as controls. All patients were followed-up for the occurrence of major adverse cardiac events (MACE). Results: There was a significant increase in serum resistin levels in patients with AMI compared to controls (3.71 ± 4.20 vs. 2.00 ± 1.05, p = 0.001, respectively). However, serum resistin levels were similar in patients with STEMI and NSTEMI. (4.26 ± 5.11 vs. 3.06 ± 2.64, p = 0.49, respectively). The patients with MACE had significantly higher levels of serum resistin levels compared to either the AMI or the control group (6.35 ± 5.47, p = 0.005, respectively). Logistic regression analysis revealed that resistin, left ventricular ejection fraction, and coronary artery bypass graft were independent predictors of MACE in AMI patients (OR = 1.11, 95% CI 1.01-1.22, p = 0.03 and OR = 3.84, 95% CI 1.26-11.71, p = 0.018, respectively). Conclusions: Serum resistin level was increased in patients with AMI and constituted a risk factor for MACE in this group.
The Tohoku Journal of Experimental Medicine, 2007
Adiponectin functions as an anti-inflammatory and antiatherogenic factor, and the decreased plasma adiponectin is a risk factor for coronary disease. The aim of this study was to determine the changes in plasma levels of adiponectin, a potential parameter for atherosclerosis, in patients underwent surgical revascularization. We included forty patients with atherosclerosis (age, 58 ± 9 years; body mass index [BMI] 26.93 ± 2.3 kg/m 2) undergoing coronary artery bypass grafting (CABG). Control group consisted of 40 healthy volunteers, matched for age, gender and BMI (age, 56 ± 6 years; BMI, 26.78 ± 2.3 kg/m 2). We measured various parameters, including high sensitive Creactive protein (hsCRP), homeostasis model assessment-insulin resistance (HOMA-IR) indexes, and adiponectin. The baseline profile of the patients before CABG showed higher levels of serum hsCRP (13.15 ± 2.40 mg/l vs 3.97 ± 1.07 mg/l) and HOMA-IR (1.86 ± 0.30 vs 1.26 ± 0.33) and lower plasma adiponectin levels (7.02 ± 2.01 μ g/ml vs 25.46 ± 3.9 μ g/ml), compared to controls (p < 0.001 for each parameter). Plasma adiponectin level was increased one month after CABG from the baseline level to 8.67 ± 2.05 μ g/ml (p < 0.001), although the level was still lower than the control value. Thus, postoperative adiponectin level might be helpful for evaluating the progression of atherosclerosis. Moreover, CABG significantly decreased hsCRP to 7.25 ± 1.89 mg/l and HOMA-IR to 1.59 ± 0.33, although these levels were higher than the controls. These results suggest that CABG decreases the cardiac risk factors in atherosclerotic patients. adiponectin; coronary artery bypass grafting; insulin sensitivity; oxidative stress
Comparison between serum resistin levels in patients with myocardial infarction and unstable angina
Background and objectives: Studies on human adipose tissue revealed that this tissue is not only an energy storing, but an endocrine organ that secrets a variety of hormones, cytokines, growth factors, and bioactive compounds, known as adipokines into the circulation that have effects on endocrine, metabolic, and inflammatory processes that take part in the control of energy homeostasis. Resistin is an adipocytokine that has been suggested to link obesity, diabetes, and atherosclerosis. Our objective was to examine the effects of some metabolic variables on the level of serum resistin in patients with acute myocardial infarction, AMI and unstable angina, UA. Also to investigate resistin levels in different demographic characteristics including smoking, gender, hypertension and family history. Method: A case control study was carried out over a period of more than 2 years (Jan 2009 to March 2012). Forty seven patients (25 with AMI and 22 with UA) were collected from the departments of cardiology in both Al-Khademiyia Teaching Hospital and Ibn Al-Nafees Hospital in Baghdad-Iraq. The control consisted of 25 healthy subjects with no history of cardiovascular disease. Serum resistin was measured using DRG Human Resistin ELISA (EIA-4194) Kit, USA for the quantitative determination by ELISA technique (Enzyme linked immunosorbant assay). Serum lipid profile, including total cholesterol, triglyceride (TG), HDL-C and LDL-C, was determined enzymatically using (Biomeueaux, France) kits .Glycosylated haemoglobin, HbA1c % was measured by colorimetric method at 415 nm using Stanbio kit, procedure No. P350. Results: A highly significant difference existed in serum resistin levels between the AMI and the UA patients as compared to their controls, and a significant difference between the two groups when compared to each other. No significant differences was found between serum resistin, lipid profile, fasting serum glucose , HbA1c and body mass index in both AMI and UA groups when they were classified according to their demographic characteristics. As concerning the relation with other metabolic variables measured serum resistin of hypertensive UA patients only showed a significant correlation with their serum total cholesterol , LDL-C and their atherogenic index (p<0.001). Conclusion: according to the study results and patients demographic characteristics, it can concluded that level of serum resistin is raised significantly in AMI and UA and may be affected by some metabolic variables independent of the demographic characteristics like smoking habits , hypertension and family history.
The Association of Resistin with Coronary Disease in the General Population
Journal of Atherosclerosis and Thrombosis, 2014
To explore the association between resistin expression and the incidence of ischemic heart disease in the general population. Methods: A follow-up study of 6636 adults recruited randomly from the general population. Results: The serum resistin concentration was higher in women (6.1 ng/mL; CI95%= 6.0-6.2) than in men (5.6 ng/mL; CI95%= 5.5-5.7). Individuals in the 5th quintile or higher of resistin (RQ5) were younger (P＜0.001) and had a lower prevalence of arterial hypertension (P＜0.001), abdominal obesity (P＜0.001), diabetes (P＜0.001) and dyslipidemia (P＜0.001). The cardiovascular risk estimated by the Framingham function was also lower in the RQ5 subgroup (P＜0.001); however, the prevalence of smoking was higher (P＜0.001), as was the prevalence of low HDL cholesterol (P＜0.001). After 3.5 years of follow-up, the RQ5 subgroup had a higher incidence of acute myocardial infarction (AMI, RR= 1.9; CI95%= 1.01-3.54). In the population without diabetes, the RQ5 subgroup had a higher risk of AMI (RR = 2.4; CI95%= 1.10-5.17), and the risk of AMI was highest in women in this group (4.97; CI95%=1.33-18.57). The risk levels were significant in the Cox models adjusted for age, sex and smoking; and the hazard ratio was 2.5 for AMI (CI95%= 1.29-4.70) in the sample of patients matched by sex and smoking status. Conclusions: Resistin may be a risk marker for ischemic heart disease in the general population. The serum resistin concentration is higher in women, and the associated increase in the risk of AMI based on the resistin level is also higher in women than in men.
Relationship Between Increased Serum Resistin Level and Severity of Coronary Artery Disease
Angiology, 2014
Resistin, which is derived from the gene of RSTN, belongs to a family of cysteine-rich secretory proteins called resistin-like molecules (RELMs). Increased serum resistin levels are associated with coronary artery disease (CAD) and the risk of cardiovascular death. Patients (n ¼ 214) with an initial diagnosis of stable angina pectoris, unstable angina pectoris, and myocardial infarction without ST-segment elevation and referred to catheter laboratory for coronary angiography were enrolled in the study. We aimed to investigate the relationship between increased serum resistin level and CAD. The severity of CAD was calculated by the Gensini scoring system. In conclusion, we established a significant correlation between serum resistin levels and CAD (P ¼ .010). Also, serum resistin levels correlated with the Gensini score that represents the severity of CAD angiographically (P ¼ .010).